Inactive Instrument

Press Releases Oncomed Pharmaceuticals Inc

Equities

US68234X1028

Press Releases

Unlock all the news: Be the first to know and act before the market!

OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights	19-03-15	GL
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results	19-03-07	GL
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals	18-12-05	GL
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody	18-11-09	GL
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer	18-10-22	GL
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer	18-10-20	GL
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting	18-10-09	GL
OncoMed to Present at the Cantor Global Healthcare Conference	18-09-24	GL
OncoMed Announces Publication of Phase 1a Data of Navicixizumab	18-09-24	GL
OncoMed Provides Update on Navicixizumab Partnership	18-09-20	GL
Oncomed Pharmaceuticals : Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial	18-06-12	PU
OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights	18-05-08	GL
OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018	18-05-01	GL
OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting	18-04-18	GL
OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting	18-04-09	GL
OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors	18-03-19	GL
OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights	18-03-08	GL
OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018	18-02-22	GL
Newman Ferrara LLP : Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - OMED	18-01-08	BU
OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned	18-01-04	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncomed Pharmaceuticals Inc

Equities

US68234X1028

Press Releases

Filters